AC Immune says Parkinson’s drug slows progression
Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson’s disease. The results of the phase 2 VacSYn trial of ACI-7104.056 in patients with early-stage Parkinson’s have shown that the immunotherapy can reduce disease-related biomarkers β namely alpha-synuclein levels in the cerebrospinal fluids (CSF)…